Olema Pharmaceuticals, Inc. (OLMA) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Olema Pharmaceuticals, Inc. (OLMA) Earnings Overview
As of June 29, 2026, Olema Pharmaceuticals, Inc. (OLMA) reported trailing twelve-month net income of -$185M, reflecting +15.0% year-over-year growth. The company earned $-1.80 per diluted share over the past four quarters.
Looking at the long-term picture, OLMA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2018.
Olema Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRRK (-$409M net income), KYMR (-$315M net income, -794.4% margin), RVMD (-$1.37B net income), OLMA has comparable earnings metrics. Compare OLMA vs SRRK →
OLMA Earnings vs Peers
Earnings metrics vs comparable public companies
OLMA Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$162M | -25.5% | -$179M | $-1.87 | - | - |
| 2024 | -$129M | -34.0% | -$142M | $-2.20 | - | - |
| 2023 | -$97M | +7.8% | -$105M | $-2.14 | - | - |
| 2022 | -$105M | -47.4% | -$107M | $-2.62 | - | - |
| 2021 | -$71M | -221.4% | -$71M | $-1.79 | - | - |
| 2020 | -$22M | -412.5% | -$22M | $-0.58 | - | - |
| 2019 | -$4M | -96.4% | -$4M | $-0.11 | - | - |
| 2018 | -$2M | - | -$2M | $-0.16 | - | - |
Download Data
Export OLMA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OLMA — Frequently Asked Questions
Quick answers to the most common questions about buying OLMA stock.
What is OLMA earnings per share (EPS)?
OLMA trailing twelve-month (TTM) diluted EPS is $-1.80, reflecting +15.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Olema Pharmaceuticals, Inc.'s net income?
Olema Pharmaceuticals, Inc. (OLMA) trailing twelve-month net income is $-185M as of 2025. Earnings grew +15.0% year-over-year.
Is OLMA profitable?
OLMA is not currently profitable on a TTM basis, reporting a net loss of $-185M. Net margin is N/A. Investors should monitor for a return to profitability.
What is OLMA's earnings growth rate?
OLMA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are OLMA's profit margins?
Olema Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -36.6%.
Is OLMA growing earnings?
OLMA is growing earnings steadily. YoY EPS growth of +15.0% is consistent with the 5-year CAGR of N/A. TTM net income is $-185M.
What was OLMA's best earnings year?
Olema Pharmaceuticals, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were OLMA's earnings last quarter?
OLMA's most recent reported quarter was Q1 2026. Net income was $-53M with diluted EPS of $-0.52. For a full breakdown of all quarters, see the quarterly earnings table on this page.